NCT03678493已完成2 期
A Randomized Placebo-Controlled Clinical Trial of Fecal Microbiota Transplantation in Patients With Acute Myeloid Leukemia and Allogeneic Hematopoietic Cell Transplantation Recipients
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 2
- 主要终点
- Efficacy of FMT in AML Patients and Allo-HCT Recipients - Number of Infections
研究概览
简要总结
This is a randomized, double-blind, placebo-controlled clinical trial of Fecal Microbiota Transplant (FMT) in 2 independent cohorts (60 acute myeloid leukemia patients undergoing intensive chemotherapy and 60 Allo-HCT patients). Participants in each cohort will be randomized in a 2:1 ratio to receive up to 3 treatments of FMT vs. placebo after each exposure to antibacterial antibiotics until 3 months after randomization.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age≥ 18 years
- •Cohort A: Patients undergoing intensive induction chemotherapy for acute myeloid leukemia (AML; newly diagnosed or relapsed/refractory).
- •* Any intensive regimen with planned ~4 weeks of inpatient stay
- •Cohort B: Allo-HCT patients
- •* Any allogeneic transplant regimen with planned GVHD prophylaxis containing generic IV Mycophenolate Mofetil (MMF) and tacrolimus (Tac)
- •Sexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control until at least six months post-FMT/placebo
- •Voluntary written consent signed before performance of any study-related procedure not part of normal medical care
排除标准
- •Planned continuation of antibacterial antibiotics after the first neutrophil recovery (ANC > 1,000)
- •Patients who are currently receiving or recently received (within 28 days) other investigational agents.
- •Pregnant or breast feeding. The FDA has not classified this agent into a specified pregnancy category. Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy
结局指标
主要结局
Efficacy of FMT in AML Patients and Allo-HCT Recipients - Number of Infections
时间窗: 4 Months
Number of infections infections until 4 months after the first intervention. Monitored each visit through safety assessment.
次要结局
- FMT Engraftment(4 Weeks after first FMT treatment)
- Number of Bacterial Infections(4 Months after first FMT treatment)
- Percentage of Participants With Grade II-IV Acute Graft-versus-host Disease (aGVHD II-IV)(Day 180 post-HCT, up to 7 months)
- Number of BSI of Suspected Gut Origin(1 week after first FMT treatment)
- Number of Fungal Infections(4 Months after first FMT treatment)
- Number of Viral Infections(4 Months after first FMT treatment)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Fecal Microbiota Transplantation for PouchitisPouchitisNCT03545386McMaster University47
尚未招募
2 期
FMT for MS PatientsMultiple SclerosisNCT04150549Lawson Health Research Institute34
已完成
2 期
Fecal Microbiota Transplantation (FMT) in the Treatment of PouchitisUlcerative ColitisPouchitisNCT03378921Helsinki University Central Hospital26
Enrolling By Invitation
不适用
Randomized Controlled Trial of Fecal Microbiota Transplantation in Severe ObesityObesity, MorbidNCT03273855University Hospital of North Norway60
招募中
1 期
Washed Microbiota Transplantation for Chronic Constipation in AdultsConstipationNCT06106685The Second Hospital of Nanjing Medical University18